Analysis of C. difficile infection–related outcomes in European participants in the bezlotoxumab MODIFY I and II trials

The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B, given during antibiotic treatment for Clostridioides difficile infection (CDI) significantly reduced C. difficile recurrence (rCDI) in adults at high risk for rCDI. Efficacy o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Clin Microbiol Infect Dis
Autors principals: Bouza, Emilio, Cornely, Oliver A., Ramos-Martinez, Antonio, Plesniak, Robert, Ellison, Misoo C., Hanson, Mary E., Dorr, Mary Beth
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497347/
https://ncbi.nlm.nih.gov/pubmed/32504314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10096-020-03935-3
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars